Beyond Traditional Chemotherapy: How Genomic Sequencing and CAR-T Cell Immunotherapy Are Redefining Cancer Care

Cancer therapy has undergone a seismic paradigm shift over the past decade. For decades, cytotoxic chemotherapy was the primary weapon, attacking both malignant and healthy cells alike and producing harsh side effects.

Today, Elyvon Comprehensive Cancer Centre employs Next-Generation Sequencing (NGS) to decode the distinct genetic mutations driving each patient's tumor. By pinpointing targetable biomarkers like EGFR, ALK, HER2, BRCA, and NTRK, oncologists can prescribe orally administered precision inhibitors that neutralize malignant pathways with remarkable specificity.

Furthermore, Chimeric Antigen Receptor (CAR) T-cell therapy represents true personalized cellular biotechnology. By extracting the patient's own defensive T-lymphocytes, inserting synthetic chimeric receptors that seek tumor markers, and re-infusing them, we create a living biological defense force capable of destroying stubborn leukemias and lymphomas.